Department of Surgery, JA Hiroshima General Hospital, Hatsukaichi, Hiroshima, 738-8503, Japan.
Department of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8551, Japan.
J Med Case Rep. 2023 Jan 16;17(1):15. doi: 10.1186/s13256-022-03735-7.
During neoadjuvant chemotherapy for giant gastrointestinal stromal tumors, changes in gastrointestinal stromal tumor size are rarely associated with events such as perforation and bleeding that require emergency surgery. Moreover, it is very rare for gastrointestinal stromal tumors to shrink and become mobile, resulting in gastric volvulus. Herein, we report a case of gastrointestinal stromal tumor shrinkage during neoadjuvant imatinib treatment, resulting in gastric volvulus that required surgery. To the best of our knowledge, this is the first reported occurrence of gastric volvulus during neoadjuvant imatinib treatment for a giant gastrointestinal stromal tumor.
A 58-year-old Japanese woman who was diagnosed with a giant gastric gastrointestinal stromal tumor and administered neoadjuvant imatinib presented to our hospital with complaints of abdominal pain and retching. Enhanced computed tomography revealed that the gastrointestinal stromal tumor had shrunk and shifted in position, and the stomach had organoaxially twisted. Accordingly, the patient was diagnosed with gastric volvulus caused by a gastric gastrointestinal stromal tumor. Conservative treatment did not improve the volvulus; hence, laparotomy was performed. The tumor developed from the lesser curvature of the stomach and caused rotation of the gastric body. The local gastric wall was resected. Histopathological examination confirmed the diagnosis of gastrointestinal stromal tumor. The patient received adjuvant imatinib for 3 years and has been alive for 5 years without recurrence.
Gastric volvulus can be caused by the laxity of the ligaments that hold the stomach and gastric ptosis or esophageal hernia and diaphragmatic hernia; therefore, gastric gastrointestinal stromal tumors rarely cause gastric volvulus. However, a risk of torsion exists if the gastrointestinal stromal tumor develops extramural to lesser curvature and attains a certain size.
在新辅助化疗治疗巨大胃肠道间质瘤期间,胃肠道间质瘤大小的变化很少与穿孔和出血等需要紧急手术的事件相关。此外,胃肠道间质瘤很少会缩小并变得移动,从而导致胃扭转。在此,我们报告一例新辅助伊马替尼治疗期间胃肠道间质瘤缩小导致胃扭转的病例,需要手术治疗。据我们所知,这是首例报道的新辅助伊马替尼治疗巨大胃肠道间质瘤期间发生胃扭转的病例。
一位 58 岁的日本女性,诊断为巨大胃胃肠道间质瘤,并接受新辅助伊马替尼治疗,因腹痛和呕吐就诊于我院。增强计算机断层扫描显示胃肠道间质瘤已缩小并移位,胃呈器官轴扭转。因此,患者被诊断为胃胃肠道间质瘤引起的胃扭转。保守治疗未能改善扭转;因此,进行了剖腹手术。肿瘤起源于胃小弯,导致胃体旋转。局部胃壁被切除。组织病理学检查证实了胃肠道间质瘤的诊断。患者接受了 3 年的辅助伊马替尼治疗,并且已经存活了 5 年,没有复发。
胃扭转可由固定胃的韧带松弛、胃下垂或食管裂孔疝和膈疝引起;因此,胃胃肠道间质瘤很少引起胃扭转。然而,如果胃肠道间质瘤向小弯外侧发展并达到一定大小,则存在扭转的风险。